Skip to main content
. Author manuscript; available in PMC: 2021 Aug 15.
Published in final edited form as: Cancer. 2020 Jun 4;126(16):3788–3799. doi: 10.1002/cncr.32996

Fig. 5. Concurrent treatment with osimertinib and trametinib combination (A) delays the emergence of osimertinib resistance in vivo (B) without enhancing toxicity (C).

Fig. 5.

A, A schema for the concurrent treatment schedule. B and C, PC-9 xenografts in nude mice (6 mice/group) were treated with vehicle, osimertinib (15 mg/kg, og, once/day), trametinib (1 mg/kg, og, once/two days) or the combination of osimertinib and trametinib. Tumor sizes and mouse body weights were measured every three days and presented as means ± SEMs.